BioWorld Asia

April 16, 2003

Celltech Poised To Acquire OGS After Other Parties Drop Interest

LONDON - Oxford GlycoSciences plc succumbed to the hostile bid from Celltech plc that will lead to the breakup of the business, after failing to attract any better offers. (BioWorld International) Read More

Oxxon Completes £15M Round To Fund Therapeutic Vaccines

Engineered Lymphocytes Show Promise In Metastatic Cancer

Karo Bio Plans To Net SEK120M From Discounted Rights Issue

Affitech, NatImmune Team Up In Colon Cancer Collaboration

Entomed, Achillion Enter Deal For Antiviral Drug Discovery

European Parliament Moves For Strict Cell, Tissue Rules

EU Consumer Commissioner Favors Progress In Biotech

IDM Acquires Cancer Assets For Stock In Deal With Jenner

Proteome Sciences, IDEXX Enter Deal To Develop BSE Diagnostic

MedPharma Looking To Go Public To Fund Sexual Dysfunction Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...